Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia

Luca Vanella; Giorgio Ivan Russo; Sebastiano Cimino; Eugenia Fragalà; Vincenzo Favilla; Giovanni Li Volti; Ignazio Barbagallo; Valeria Sorrenti; Giuseppe Morgia

doi:10.1016/j.urology.2014.03.007

Correlation between lipid profile and heme oxygenase system in patients with benign prostatic hyperplasia

Urology. 2014 Jun;83(6):1444.e7-13. doi: 10.1016/j.urology.2014.03.007.

Authors

Luca Vanella¹, Giorgio Ivan Russo², Sebastiano Cimino³, Eugenia Fragalà³, Vincenzo Favilla³, Giovanni Li Volti¹, Ignazio Barbagallo¹, Valeria Sorrenti¹, Giuseppe Morgia³

Affiliations

¹ Department of Drug Science, Biochemistry Section, University of Catania, Catania, Italy.
² Department of Urology, Policlinico Hospital, University of Catania, Catania, Italy. Electronic address: giorgioivan@virgilio.it.
³ Department of Urology, Policlinico Hospital, University of Catania, Catania, Italy.

PMID: 24862399
DOI: 10.1016/j.urology.2014.03.007

Abstract

Objective: To investigate the role of heme oxygenase (HO) system in moderate to severe benign prostatic hyperplasia and lower urinary tract symptom patients and the influence of metabolic syndrome (MetS) components on HO-1 or HO-2 prostatic levels.

Methods: One hundred thirty-two consecutive patients who underwent transurethral resection of the prostate were prospectively enrolled. MetS was defined by the International Diabetes Federation. Patients were divided in 2 groups: group A (high-density lipoprotein-cholesterol [HDL-C]≥40 mg/dL and triglycerides<150 mg/dL) and group B (HDL-C<40 mg/dL and triglycerides≥150 mg/dL). Surgical specimens were collected for HO level determination. HO-1 levels were determined by enzyme-linked immunosorbent assay and HO-1 levels by Western blotting.

Results: Patients with MetS showed lower levels of HO-1 (5.29 vs 6.28 ng/mL; P=.04), HO-2 (1.01 vs 1.83 ng/mL; P=.04), phosphorylated activated protein kinase (pAMPK; 0.62 vs 1.11 AUI; P<.01), and HO-activity (61.43 vs 70.22 AUI; P<.01) with respect to normal. The Pearson correlation analysis showed that HO-1, HO-2, and HO activity were negatively associated with waist circumference (P<.05), body mass index (P<.05), triglycerides (P<.05) and positively with HDL-C (P<.05). Group B showed lower levels of HO-1 (4.7 vs 6.6 ng/mL; P<.05), HO-2 (1.4 vs 0.4 ng/mL; P=.03), HO-activity (69.63 vs 58.42 AUI; P=.04), and higher International Prostate Symptoms Score (21.4 vs 25.0; P<.05) with respect to group A. The enzyme-linked immunosorbent assay showed that HO-1 and HO activity levels were significantly lower in group B compared with group A. Reduced HDL-C and elevated triglyceride levels decreased HO-1 expression in the prostate tissue. Western blot analysis of tissue samples showed significant differences in basal protein expression levels of HO-2 and pAMPK in group B compared with group A.

Conclusion: Alteration of serum triglycerides and HDL-C significantly impairs HO-1 and HO-2 levels in benign prostatic hyperplasia patients.

MeSH terms

Aged
Aged, 80 and over
Blotting, Western
Cholesterol, HDL / blood
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Heme Oxygenase (Decyclizing) / blood*
Humans
Lower Urinary Tract Symptoms / blood*
Lower Urinary Tract Symptoms / complications
Lower Urinary Tract Symptoms / pathology
Male
Metabolic Syndrome / blood
Metabolic Syndrome / complications
Middle Aged
Prognosis
Prospective Studies
Prostatic Hyperplasia / blood*
Prostatic Hyperplasia / complications
Prostatic Hyperplasia / pathology*
Prostatic Hyperplasia / surgery
Sensitivity and Specificity
Transurethral Resection of Prostate / methods
Triglycerides / blood*

Substances

Cholesterol, HDL
Triglycerides
Heme Oxygenase (Decyclizing)
heme oxygenase-2